Groundbreaking research by Elevian’s scientific co-founders (including three Professors from the Harvard Stem Cell Institute) demonstrated that young blood rejuvenates aged animals.
They further discovered that replenishing the protein “GDF11” in aged animals can reproduce the regenerative effects of young blood – research published in Cell and Science and recognized as a top scientific breakthrough!
In animal models, GDF11 has been demonstrated to treat more than a dozen age-related diseases, including heart failure, heart attacks, stroke, Type 2 diabetes, obesity, Alzheimer’s Disease, COPD/emphysema, liver failure, kidney failure and cancer
Elevian has acquired exclusive worldwide patent rights to Harvard’s GDF11 technology. They are developing new medicines that target GDF11, with the potential to treat and prevent many age-related diseases at the same time.
Elevian’s first application uses GDF11 to treat stroke, the #2 cause of death and #1 cause of long-term disability globally. In animal models, GDF11 promotes motor function recovery and survival after stroke.
WHAT YOU WILL LEARN BY ATTENDING THE WEBINAR
Aging is malleable – It is possible to accelerate, slow and even reverse biological aging.
GDF11 plays an important role in aging – Preclinical results suggests that GDF11 has the potential to treat and prevent MANY age-related diseases and promote healthy aging.
Elevian is an exciting investment opportunity – Including a team of leading scientists and drug development veterans, a massive market opportunity, and enormous societal benefit.
